ArticleThe Lancet regional health. Western Pacific2020
Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study.
Article in The Lancet regional health. Western Pacific, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07653984 (Cohort Study on Neuroimmune Diseases in the Reproductive Age), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.Journal of neurology · 2024Pooled it
- Dynamic characterization of pathological and functional deterioration in a mouse model of optic neuritis related to neuromyelitis optica spectrum disorder.Neural regeneration research · 2026Article
- Clinicoradiologic profile of neuromyelitis optica spectrum disorder in a Kashmiri cohort: a prospective observational cohort study.Encephalitis (Seoul, Korea) · 2026Article
- Health-related quality of life and its associated factors among patients with neuromyelitis optica spectrum disorder in China: a questionnaire survey analysis.Health and quality of life outcomes · 2026Article
- Hospitalization costs and out-of-pocket expenses for stroke patients in mainland China.BMC health services research · 2026Article
- Demyelinating disorders in women: epidemiology, immunology, and clinical implications across MS, NMOSD, and MOGAD.Journal of neurology · 2026Review
- Financial Toxicity in Neuromyelitis Optica Spectrum Disorder: An ABC-X Mixed-Methods Study.Brain and behavior · 2026Article
- Article
- Neuromyelitis optica spectrum disorder patients dyadic coping patterns: a latent profile analysis.Frontiers in psychology · 2026Article
- Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.Journal of neurology · 2025Article
- Acute neuromyelitis optica spectrum disorder patients' clinical analysis of disability-related biomarkers.BMC neurology · 2025Article
- Case Report: Organizing pneumonia associated with AQP4-antibody neuromyelitis optica spectrum disorder in children.Frontiers in pediatrics · 2025Article
- The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population.Annals of clinical and translational neurology · 2025Observational
- Environmental risk factors of neuromyelitis optica spectrum disorder: a systematic review.Therapeutic advances in neurological disorders · 2025Review
- Prediction of apolipoprotein A-I and high-density lipoprotein cholesterol in the neurological impairment and relapse of neuromyelitis optica spectrum disorder.Frontiers in neuroscience · 2025Article
- A Chinese girl with neuromyelitis optica spectrum disorder coexisting with primary Sjogren's syndrome: a case report and literature review.Frontiers in immunology · 2025Review
- Article
- Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab.Frontiers in neurology · 2025Article
- Very-late-onset neuromyelitis optica spectrum disorder: a case report and review.Frontiers in neurology · 2025Article
- CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.Journal of neuroinflammation · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuromyelitis Optica Spectrum Disorder (NMOSD) is an inflammatory disease of the central nervous system with preferential involvement of the optic nerve and spinal cord. However, data on NMOSD incidences in China, a country encompassing 20% of the world's population and covering vast areas of Eastern Asia, are unknown.
methodsWe conducted the first nationwide survey of NMOSD, based on the database of the National Hospital Quality Monitoring System (HQMS) of China, which covers all 1665 tertiary hospitals. The "Medical Record Homepage" of all patients were consistently collected via a standard protocol across each tertiary hospital. The primary outcome was the incidence of NMOSD, diagnosed according to the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria and identified by ICD-10 code (G36•0). Burden of hospitalization, comorbidities, and death were also evaluated.
findingsWe identified 33,489 hospital admissions for 17,416 NMOSD diagnosed patients from 2016 to 2018. 11,973 patients were newly diagnosed NMOSD. The age and sex adjusted incidence per 100,000 person years was 0•278 (95% confidence interval [CI], 0•273-0•283), with 0•075 (0•069-0•08) in child and 0•347 (0•34-0•353) in adult. The peak age of onset NMOSD is 45-65 years with an incidence 0•445/100,000 (95% CI, 0•433-0•457). The female to male ratio was 4•71 (
interpretationThe incidence of NMOSD in China per 100,000 person years was 0•278, with 0•075 in child and 0•347 in adult. The geographical distribution of NMOSD is not related to the latitude gradient.
fundingNational Science Foundation of China (91949208, 91642205, and 81830038); Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.